True Wealth Design
IKT icon

True Wealth Design’s Inhibikase Therapeutics IKT Stock Holding History

True Wealth Design’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$496 Sell
241
-258
-52% -$587 ﹤0.01% 2132
2026
Q2 		$1.01K Buy
499
+456
+1,060% +$816 ﹤0.01% 1971
2026
Q1 		$73 Buy
+43
New +$76 ﹤0.01% 2515

Other funds holding IKT

Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

True Wealth Design's IKT Position: Q3 2026 in Review

True Wealth Design reduced its Inhibikase Therapeutics (IKT) stake by 52% in Q3 2026, selling an estimated $587 and leaving 241 shares worth $496. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

True Wealth Design first reported a position in IKT in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.01K in Q2 2026. 8 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • True Wealth Design held 241 shares of Inhibikase Therapeutics worth $496 as of Q3 2026.
  • True Wealth Design sold 258 Inhibikase Therapeutics shares in Q3 2026, an estimated $587.
  • Inhibikase Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2132 holding.
  • True Wealth Design first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • True Wealth Design's Inhibikase Therapeutics position peaked at $1.01K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.